Literature DB >> 20152234

Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.

Stefan Brunner1, Jong-Oh Kim, Heiko Methe.   

Abstract

Atherosclerosis is an inflammatory disease in which systemic inflammation correlates with disease activity. Matrix metalloproteinases (MMPs) contribute to collagen breakdown in atherosclerotic plaques. In the present study, we investigated whether the ratio of MMP-9 and its endogenous inhibitor, tissue inhibitor of metalloproteinase (TIMP)-1, in circulating monocytes correlates with the clinical stages of coronary artery disease. We studied 18 patients with stable angina pectoris (SAP), 14 patients with unstable angina pectoris and non-ST-segment elevation myocardial infarction (UAP/NSTEMI), 14 patients with ST-elevation myocardial infarction (STEMI), and 16 healthy controls. The protein and mRNA levels of MMP-9 and TIMP-1 in CD14+ monocytes were analyzed using real-time polymerase chain reaction and enzyme-linked immunosorbent assay. The activity of serum MMP-9 was assessed using zymography. Compared to the controls (0.07 +/- 0.01 relative units) and patients with SAP (0.25 +/- 0.1 relative units, p = NS), the monocytic MMP-9 mRNA levels were increased in those with UAP/NSTEMI (0.9 +/- 0.3 relative units, p <0.05 vs SAP) or STEMI (1.6 +/- 0.4 relative units, p <0.05 vs UAP/NSTEMI). In contrast, the protein and mRNA expression of monocytic TIMP-1 levels was 4.5- to 4.7-fold lower in patients with STEMI than in the controls or those with SAP or UAP/NSTEMI (p <0.05). Changes in monocytic expression of MMP-9 and TIMP-1 tracked with the serum levels of MMP-9 and TIMP-1. The activity of serum MMP-9 correlated with the individual MMP-9/TIMP-1 ratio in the peripheral circulating monocytes (r(2) = 0.82, p <0.02). In conclusion, the progression of coronary artery disease was mirrored by an increasing MMP-9/TIMP-1 ratio in the peripheral circulating CD14+ monocytes and serum, respectively. Circulating monocytes displayed the same pattern of imbalance in the expression of MMP-9 and TIMP-1 as previously reported for monocyte-derived macrophages within atherosclerotic plaques, supporting the notion of atherosclerosis as a systemic inflammatory disease. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20152234     DOI: 10.1016/j.amjcard.2009.10.013

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

3.  Augmented expression and activity of extracellular matrix-degrading enzymes in regions of low endothelial shear stress colocalize with coronary atheromata with thin fibrous caps in pigs.

Authors:  Yiannis S Chatzizisis; Aaron B Baker; Galina K Sukhova; Konstantinos C Koskinas; Michail I Papafaklis; Roy Beigel; Michael Jonas; Ahmet U Coskun; Benjamin V Stone; Charles Maynard; Guo-Ping Shi; Peter Libby; Charles L Feldman; Elazer R Edelman; Peter H Stone
Journal:  Circulation       Date:  2011-01-31       Impact factor: 29.690

Review 4.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

5.  Matrix metalloproteinases 2 and 9 are differentially expressed in patients with indeterminate and cardiac clinical forms of Chagas disease.

Authors:  Rafaelle Christine Gomes Fares; Juliana de Assis Silva Gomes; Luciana Ribeiro Garzoni; Mariana Caldas Waghabi; Roberto Magalhães Saraiva; Nayara Ingrid Medeiros; Roberta Oliveira-Prado; Luiz Henrique Conde Sangenis; Mayara da Costa Chambela; Fernanda Fortes de Araújo; Andréa Teixeira-Carvalho; Marcos Paulo Damásio; Vanessa Azevedo Valente; Karine Silvestre Ferreira; Giovane Rodrigo Sousa; Manoel Otávio da Costa Rocha; Rodrigo Correa-Oliveira
Journal:  Infect Immun       Date:  2013-07-15       Impact factor: 3.441

6.  Imbalances between matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in maternal serum during preterm labor.

Authors:  Inge Tency; Hans Verstraelen; Ivo Kroes; Gabriële Holtappels; Bruno Verhasselt; Mario Vaneechoutte; Rita Verhelst; Marleen Temmerman
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

7.  Increased levels of leukocyte-derived MMP-9 in patients with stable angina pectoris.

Authors:  Simon Jönsson; Anna Lundberg; Hanna Kälvegren; Ida Bergström; Aleksander Szymanowski; Lena Jonasson
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

8.  Relationship Between MMP-1, MMP-9, TIMP-1, IL-6 and Risk Factors, Clinical Presentation, Extent and Severity of Atherosclerotic Coronary Artery Disease.

Authors:  Asli Tanindi; Asife Sahinarslan; Sehri Elbeg; Mustafa Cemri
Journal:  Open Cardiovasc Med J       Date:  2011-05-13

9.  Interferon-gamma increases the ratio of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in peripheral monocytes from patients with coronary artery disease.

Authors:  Rashidi Springall; Luis M Amezcua-Guerra; Hector Gonzalez-Pacheco; Janette Furuzawa-Carballeda; Lorena Gomez-Garcia; Ricardo Marquez-Velasco; Ana María Mejía-Domínguez; Jorge Cossío-Aranda; Carlos Martínez-Sánchez; Rafael Bojalil
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

10.  Overexpression of MMP-9 and its inhibitors in blood mononuclear cells after myocardial infarction--is it associated with depressive symptomatology?

Authors:  Simon Jönsson; Anna K Lundberg; Lena Jonasson
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.